{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:52:07Z","timestamp":1790016727243,"version":"4.0.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:p>\n                    Nucleos(t)ide analogues (NAs) have demonstrated potent efficacy in suppressing viral replication in chronic hepatitis B (CHB). This 48-week study compared the efficacy and safety of NA treatment for CHB patients with high viral load (hepatitis B virus [HBV] deoxyribonucleic acid [DNA]\u2005&gt;\u20057 log\n                    <jats:sub>10<\/jats:sub>\n                    IU\/mL). This retrospective study included 180 nucleos(t)ide-na\u00efve CHB patients with high viral load undergoing NA monotherapy, which were stratified into 3 groups: entecavir (ETV, n\u2005=\u200582), tenofovir disoproxil fumarate (TDF, n\u2005=\u200558), and tenofovir alafenamide fumarate (TAF, n\u2005=\u200540). The primary endpoint was the proportion of patients achieving HBV DNA\u2005&lt;\u200520 IU\/mL, with safety assessed by lipid profiles and renal function. The study subjects\u2019 mean baseline HBV DNA levels were 7.68, 7.73, and 7.75 log\n                    <jats:sub>10<\/jats:sub>\n                    IU\/mL in ETV, TDF, and TAF groups, respectively. At week 48, TDF had a higher viral suppression (HBV DNA\u2005&lt;\u200520 IU\/mL) rate (67.74%) than TAF (37.50%) cohort (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.004) and ETV (54.88%) was comparable to both (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). Hepatitis B e antigen loss and seroconversion were comparable across all groups, with no hepatitis B surface antigen loss observed. Similar proportions of patients with high alanine aminotransferase levels at baseline achieved normalization by week 48 in all regimens. Low-density lipoprotein, total cholesterol, and triglyceride elevations were comparable across all groups. High-density lipoprotein reductions were 15.63%, 35.71%, and 17.86% in ETV, TDF, and TAF, respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.043), with TDF reducing high-density lipoprotein and total cholesterol more than ETV (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.014 and\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). No significant differences were found in serum creatinine elevation or estimated glomerular filtration rates reduction among the groups. TDF was preferentially recommended for high viral load CHB patients, as its superior antiviral efficacy and comparable safety profile.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000043946","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T19:01:57Z","timestamp":1756494117000},"page":"e43946","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of efficacy and safety of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate treatment in patients with high viral load of hepatitis B virus"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0170-4792","authenticated-orcid":false,"given":"Chenxia","family":"Zhang","sequence":"first","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China"},{"name":"Department of Infectious Diseases, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Chen","sequence":"additional","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China"},{"name":"Department of Infectious Diseases, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehua","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Information Technology, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3341-1917","authenticated-orcid":false,"given":"Yuanwang","family":"Qiu","sequence":"additional","affiliation":[{"name":"Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China"},{"name":"Department of Infectious Diseases, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.mcna.2013.08.004","article-title":"Chronic hepatitis B virus infection.","volume":"98","author":"McMahon","year":"2014","journal-title":"Med Clin North Am"},{"key":"R3-20260406","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection \u2013 natural history and clinical consequences.","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors.","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"R5-20260406","doi-asserted-by":"crossref","first-page":"e32189","DOI":"10.1371\/journal.pone.0032189","article-title":"Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation.","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS One"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.clnu.2011.05.001","article-title":"Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B.","volume":"30","author":"Lee","year":"2011","journal-title":"Clin Nutr"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/carcin\/bgm252","article-title":"Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men.","volume":"29","author":"Wu","year":"2008","journal-title":"Carcinogenesis"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/cid\/cix747","article-title":"Higher mortality despite early antiretroviral therapy in human immunodeficiency virus and hepatitis B virus (HBV)\u2013coinfected patients with high HBV replication.","volume":"66","author":"Kouam\u00e9","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R9-20260406","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B.","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta\u2010analysis.","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"R11-20260406","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"R12-20260406","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C.","volume":"49","author":"Kau","year":"2008","journal-title":"J Hepatol"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B.","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2893.2009.01168.x","article-title":"Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa.","volume":"17","author":"Mendy","year":"2010","journal-title":"J Viral Hepat"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/jgh.12898","article-title":"Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.","volume":"30","author":"Lim","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"R16-20260406","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s11605-010-1211-1","article-title":"High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection.","volume":"14","author":"Qu","year":"2010","journal-title":"J Gastrointest Surg"},{"key":"R17-20260406","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000324197","article-title":"High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence.","volume":"84","author":"Li","year":"2011","journal-title":"Digestion"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"R19-20260406","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clinre.2014.09.009","article-title":"Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load.","volume":"39","author":"Yan","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009.","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"R21-20260406","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"R22-20260406","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A New Equation to Estimate Glomerular Filtration Rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"R23-20260406","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"R25-20260406","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.intimp.2016.11.022","article-title":"The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: a systematic review and Meta-analysis.","volume":"42","author":"Han","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"R26-20260406","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"R27-20260406","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12072-008-9065-2","article-title":"Should chronic HBV infected patients with normal ALT treated: debate.","volume":"2","author":"Sarin","year":"2008","journal-title":"Hepatol Int"},{"key":"R28-20260406","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.cgh.2017.01.032","article-title":"Factors associated with persistent increase in level of alanine aminotransferase in patients with chronic hepatitis B receiving oral antiviral therapy.","volume":"15","author":"Jacobson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R29-20260406","doi-asserted-by":"crossref","first-page":"e25702","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from TDF to TAF in a U.S. cohort study.","volume":"24","author":"Mallon","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"R30-20260406","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.","volume":"61","author":"Santos","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R31-20260406","doi-asserted-by":"crossref","first-page":"155395","DOI":"10.1016\/j.metabol.2022.155395","article-title":"Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures.","volume":"141","author":"Ritou","year":"2023","journal-title":"Metabolism"},{"key":"R32-20260406","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int"},{"key":"R33-20260406","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/ki.2010.318","article-title":"Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.","volume":"78","author":"Herlitz","year":"2010","journal-title":"Kidney Int"},{"key":"R34-20260406","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/labinvest.2009.14","article-title":"Tenofovir renal toxicity targets mitochondria of renal proximal tubules.","volume":"89","author":"Kohler","year":"2009","journal-title":"Lab Invest"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:01:34Z","timestamp":1775455294000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":32,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043946","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"2024-12-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}